Sucampo Pharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | |
|---|---|---|---|---|---|---|
| Revenue | $47.2M | $29.5M | $115.5M | $89.6M | $81.5M | $54.8M |
| Operating income | −$503,000 | $9.7M | $27.2M | $9.2M | $8.3M | −$17.7M |
| Net income | −$4.1M | $6.4M | $13.1M | $7.0M | $5.1M | −$17.3M |
| Total assets | $520.9M | $457.2M | $141.6M | $136.9M | $127.8M | $157.6M |
| Total liabilities | $353.8M | $370.7M | $59.3M | $77.9M | $84.8M | $119.0M |
| Equity | $167.1M | $86.4M | $82.3M | $59.0M | $43.3M | $38.6M |
| EPS (diluted) | $-0.10 | $0.14 | $0.29 | $0.16 | $0.12 | $-0.41 |
| Shares out. | 45.5M | 44.9M | 44.0M | 42.0M | 41.8M | 41.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- −1.1%
- Net margin
- −8.6%
- Return on equity
- −2.4%
- Return on assets
- −0.8%
- Return on capital (ROCE)
- −0.1%
- Liabilities / assets
- 67.9%
- Debt / equity
- 2.12×
- Book value / share
- $3.67
- Revenue growth (YoY)
- 60.1%
- Net income growth (YoY)
- −163.3%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Altman Z″ (distress)
- 4.19safe
- Accruals / assets
- −2.4%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Amended charter or bylawsFeb 13, 2018
- Other material eventJan 2, 2018
- Entered a material agreement · Director / officer change · Other material eventDec 26, 2017
- Regulation FD disclosureNov 16, 2017
- Results of operations · Regulation FD disclosureNov 1, 2017
- Regulation FD disclosureSep 26, 2017
- Director / officer changeSep 20, 2017
- Entered a material agreementSep 8, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BFeb 23, 2018
- EFFECTFeb 15, 2018
- EFFECTFeb 15, 2018
- EFFECTFeb 15, 2018
- EFFECTFeb 15, 2018
- SC 13D/AFeb 15, 2018
- SC 13D/AFeb 15, 2018
- 4FORM 4 SUBMISSIONFeb 14, 2018
- 4FORM 4 SUBMISSIONFeb 14, 2018
- 4OWNERSHIP DOCUMENTFeb 13, 2018
- 4OWNERSHIP DOCUMENTFeb 13, 2018
- 4FORM 4Feb 13, 2018
- 4FORM 4Feb 13, 2018
- 4OWNERSHIP DOCUMENTFeb 13, 2018
- 4OWNERSHIP DOCUMENTFeb 13, 2018
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.